These differences are minor for GHK-CU and should not influence site selection significantly
But I honestly believe that this complaint is rooted in the fact that these companies that arent backed by massive organizations that line pockets in DC have found a way to give themselves a competitive edge NOT in actual concern for human beings themselves
discussed potential projects with and has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industries and academia worldwide, including, but not limited to, pharmaceutical corporations like Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Medigene, Arbormed, BioSyngen and others
Since the majority of therapies in Eli Lilly obesity pipeline are GLP-1 based, their launch will substantially expand GLP-1 market share in the weight loss injection treatments
Both times are highly effective
In the US, Ozempic costs more than $1000/mth